Chemgenex gets milestone from Vernalis
Wednesday, 23 February, 2005
Chemgenex Pharmaceuticals (ASX:CXS) will receive a AUD$720,000 milestone payment from its partner Vernalis for progress made on its depression and anxiety target discovery program.
The companies entered into a partnership agreement in August last year, which is worth as much as $2 million in the first year depending on the achievement of milestones, and are working on a further licensing and collaboration agreement. To date, the company has identified ten novel genes and proteins associated with depression and anxiety.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
